Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Corporate Executive VP & CCO | November 07, 2024 | November 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date November 07, 2024 · Filed November 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 23,337 |
Reported balance
After 2024-11-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-11-07 · Gift · Disposed 470 · Balance 23,337 F1: Reflects the exempt transfer pursuant to Rule 16a-13 of 965 shares held by the reporting person to William D. Barbo Revocable Trust. |
| Common StockSEC Table I · non-derivative | Direct | 2,468 |
Reported balance
Holding disclosure · report date 2024-11-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,468 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the exempt transfer pursuant to Rule 16a-13 of 965 shares held by the reporting person to William D. Barbo Revocable Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $407.45 | $203,724.00 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 13 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,571 F8 · price: This transaction was executed in multiple trades at prices ranging from $407.28 to $407.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: 4,915 shares were transferred from Trust to Direct Holdings. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 7 | $406.52 | $2,845.64 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 12 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,071 F1 · balance_after: 4,915 shares were transferred from Trust to Direct Holdings. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,685 | $405.58 | $683,398.42 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 11 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,078 F7 · price: This transaction was executed in multiple trades at prices ranging from $405.20 to $406.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: 4,915 shares were transferred from Trust to Direct Holdings. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 692 | $404.82 | $280,134.13 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 10 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,763 F6 · price: This transaction was executed in multiple trades at prices ranging from $404.16 to $405.005. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: 4,915 shares were transferred from Trust to Direct Holdings. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 726 | $403.60 | $293,012.00 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 9 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,455 F5 · price: This transaction was executed in multiple trades at prices ranging from $403.175 to $403.915. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: 4,915 shares were transferred from Trust to Direct Holdings. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,380 | $402.64 | $958,293.20 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 8 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,181 F4 · price: This transaction was executed in multiple trades at prices ranging from $402.26 to $403.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: 4,915 shares were transferred from Trust to Direct Holdings. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,253 | $401.62 | $1,306,483.20 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 7 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,561 F3 · price: This transaction was executed in multiple trades at prices ranging from $401.15 to $402.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: 4,915 shares were transferred from Trust to Direct Holdings. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,944 | $400.83 | $1,180,044.99 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 6 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,814 F2 · price: This transaction was executed in multiple trades at prices ranging from $400.15 to $401.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: 4,915 shares were transferred from Trust to Direct Holdings. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 1,513 | $179.66 | $271,825.58 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 5 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 4,915 shares were transferred from Trust to Direct Holdings. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 2,755 | $144.67 | $398,565.85 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 4,915 shares were transferred from Trust to Direct Holdings. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,204 | $109.34 | $350,325.36 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 4,915 shares were transferred from Trust to Direct Holdings. Read SEC document |
| June 09, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 252 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 12,312 F1 · balance_after: 4,915 shares were transferred from Trust to Direct Holdings. Read SEC document |
| June 09, 2021 Filed Aug 10, 2021 15:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 252 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023431 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,371 Read SEC document |
| May 29, 2021 Filed Jun 1, 2021 21:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 201 | $337.99 | $67,935.99 |
DisclosureSEC source: 0001127602-21-018558 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,623 Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 21:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 3,110 | $337.99 Strike: $337.99 | $1,051,148.90 |
DisclosureSEC source: 0001127602-21-018558 · form4.xml · derivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,110 Underlying: Common Stock · 3,110 shares Expires 2031-05-28 F2 · shares: Stock Options vest as follows: 777 on May 28, 2022, 778 on May 28, 2023, 777 on May 28, 2024 and 778 on May 28, 2025. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 21:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-018558 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,824 F1 · shares: Unvested restricted stock units vest as follows: 251 on May 28, 2022, 252 on May 28, 2023, 251 on May 28, 2024 and 252 on May 28, 2025. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,493 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-21-008726 · form4.xml · derivative · entry 6 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,493 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,157 | $290.43 | $336,028.20 |
DisclosureSEC source: 0001127602-21-008726 · form4.xml · nonDerivative · entry 5 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 16,975 F2 · price: This transaction was executed in multiple trades at prices ranging from $290.428 to $290.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,493 | $290.10 | $1,013,311.62 |
DisclosureSEC source: 0001127602-21-008726 · form4.xml · nonDerivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,818 F1 · price: This transaction was executed in multiple trades at prices ranging from $290.00 to $290.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,493 | $88.05 | $307,558.65 |
DisclosureSEC source: 0001127602-21-008726 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 21:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 1,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-008726 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 18,132 Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 21:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 1,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-008726 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,818 Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 322 | $282.98 | $91,119.56 |
DisclosureSEC source: 0001127602-21-007883 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,975 Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 16:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 315 | $283.59 | $89,330.85 |
DisclosureSEC source: 0001127602-21-007536 · form4.xml · nonDerivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,297 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 287 | $289.55 | $83,100.85 |
DisclosureSEC source: 0001127602-21-007536 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,612 Read SEC document |
| February 04, 2021 Filed Feb 24, 2021 16:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 7,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-007536 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 16,975 Read SEC document |
| February 04, 2021 Filed Feb 24, 2021 16:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 7,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-007536 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,899 Read SEC document |
| February 02, 2021 Filed Feb 2, 2021 15:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 4,708 | $260.88 | $1,228,223.04 |
DisclosureSEC source: 0001127602-21-003419 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,053 Read SEC document |
| February 02, 2021 Filed Feb 2, 2021 15:48 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 11,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-003419 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,761 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 23, 2018. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 20:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,150 | $236.29 | $508,015.12 |
DisclosureSEC source: 0001127602-20-028232 · form4.xml · nonDerivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 9,821 F1 · price: This transaction was executed in multiple trades at prices ranging from $236.267 to $236.361. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 30, 2020 Filed Nov 5, 2020 20:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 180 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028232 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 11,971 Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 18:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 6,054 | $0.00 Strike: $179.66 | $0.00 |
DisclosureSEC source: 0001127602-20-018384 · form4.xml · derivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,054 Underlying: Common Stock · 6,054 shares Expires 2030-05-29 F2 · shares: Stock Options vest as follows: 1,513 on May 29, 2021, 1,514 on May 29, 2022, 1,513 on May 29, 2023 and 1,514 on May 29, 2024. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 18:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018384 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,050 F1 · shares: Unvested restricted stock units vest as follows: 453 on May 29, 2021, 454 on May 29, 2022, 454 on May 29, 2023 and 454 on May 29, 2024. Read SEC document |
| March 23, 2020 Filed Nov 5, 2020 20:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 12,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028232 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 12,151 Read SEC document |
| March 23, 2020 Filed Nov 5, 2020 20:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 12,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028232 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,899 Read SEC document |
| March 05, 2020 Filed Mar 6, 2020 20:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,755 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-20-009777 · form4.xml · derivative · entry 10 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,266 Underlying: Common Stock · 2,755 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2020 Filed Mar 6, 2020 20:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,205 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-20-009777 · form4.xml · derivative · entry 9 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,409 Underlying: Common Stock · 3,205 shares Expires 2023-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2020 Filed Mar 6, 2020 20:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,492 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-20-009777 · form4.xml · derivative · entry 8 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,493 Underlying: Common Stock · 3,492 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2020 Filed Mar 6, 2020 20:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,015 | $0.00 Strike: $73.70 | $0.00 |
DisclosureSEC source: 0001127602-20-009777 · form4.xml · derivative · entry 7 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,015 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2020 Filed Mar 6, 2020 20:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 5,005 | $164.81 | $824,851.53 |
DisclosureSEC source: 0001127602-20-009777 · form4.xml · nonDerivative · entry 6 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,235 F2 · price: This transaction was executed in multiple trades at prices ranging from $164.59 to $165.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 05, 2020 Filed Mar 6, 2020 20:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 8,961 | $164.09 | $1,470,448.13 |
DisclosureSEC source: 0001127602-20-009777 · form4.xml · nonDerivative · entry 5 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,240 F1 · price: This transaction was executed in multiple trades at prices ranging from $163.56 to $164.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 05, 2020 Filed Mar 6, 2020 20:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 2,755 | $144.67 | $398,565.85 |
DisclosureSEC source: 0001127602-20-009777 · form4.xml · nonDerivative · entry 4 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2020 Filed Mar 6, 2020 20:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,205 | $109.34 | $350,434.70 |
DisclosureSEC source: 0001127602-20-009777 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2020 Filed Mar 6, 2020 20:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,492 | $88.05 | $307,470.60 |
DisclosureSEC source: 0001127602-20-009777 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2020 Filed Mar 6, 2020 20:50 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,015 | $73.70 | $222,205.50 |
DisclosureSEC source: 0001127602-20-009777 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 26, 2020 17:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 273 | $162.46 | $44,351.58 |
DisclosureSEC source: 0001127602-20-007871 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,734 Read SEC document |
| February 24, 2020 Filed Feb 24, 2020 17:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 322 | $173.64 | $55,912.08 |
DisclosureSEC source: 0001127602-20-007134 · form4.xml · nonDerivative · entry 3 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,007 Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 17:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 315 | $173.64 | $54,696.60 |
DisclosureSEC source: 0001127602-20-007134 · form4.xml · nonDerivative · entry 2 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,329 Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 17:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 287 | $173.64 | $49,834.68 |
DisclosureSEC source: 0001127602-20-007134 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,644 Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 17:01 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 6,901 | $172.11 | $1,187,698.68 |
DisclosureSEC source: 0001127602-20-005459 · form4.xml · nonDerivative · entry 1 Barbo William D · CIK 0001688104 · Corporate Executive VP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,931 F1 · price: This transaction was executed in multiple trades at prices ranging from $171.94 to $172.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.